MedTrace Logo

Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC

NCT06034964 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-09-13

No results posted yet for this study

Summary

This is a single-center, retrospective clinical study to evaluate the efficacy and safety of tislelizumab combined with first-line chemotherapy in the treatment of HER2-negative advanced gastric cancer.

Conditions

  • Tislelizumab
  • Chemotherapy
  • First-line
  • Gastric Cancer Stage IV

Interventions

DRUG

Tislelizumab

Tislelizumab：200mg, iv, d1, 21 days per cycle, until disease progression or intolerable toxicity

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Principal Investigators

  • Lin Yang · Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2022-11-01
Completion
2025-11-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06034964 on ClinicalTrials.gov